Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-21-039810

Chief Business Officer sold 7,500 shares at an average $29.37 ($220,248)

  • Chief Business Officer acquired 7,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Beaurang Pierre · Chief Business Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2021-06-10 Exercise or conversion : show line 1 in the form +7,500 $1.11 $8,325 11,830 D
2021-06-10 Sale : show line 2 in the form −6,000 $29.15 $174,881 5,830 D
2021-06-10 Sale : show line 3 in the form −1,100 $30.01 $33,006 4,730 D
2021-06-10 Sale : show line 4 in the form −400 $30.90 $12,361 4,330 D
Open-market sales · 7,500 sh · avg $29.37 · $220,248

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2021-06-10 Exercise or conversion : show line 5 in the form Employee Stock Option (right to buy) −7,500 $1.11 2027-02-01 7,500 21,562 D
Loading xslF345X03/doc4.xml…